Display options
Cite
Tian PW, Wen FQ. Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. J Transl Int Med. 2015;3(3):89-92doi: 10.1515/jtim-2015-0013.
Tian, P. W., & Wen, F. Q. (2015). Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. Journal of translational internal medicine, 3(3), 89-92. https://doi.org/10.1515/jtim-2015-0013
Tian, Pan-Wen, and Wen, Fu-Qiang. "Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease." Journal of translational internal medicine vol. 3,3 (2015): 89-92. doi: https://doi.org/10.1515/jtim-2015-0013
Tian PW, Wen FQ. Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. J Transl Int Med. 2015 Jun-Sep;3(3):89-92. doi: 10.1515/jtim-2015-0013. Epub 2015 Sep 30. PMID: 27847895; PMCID: PMC4936458.
Copy Download .nbib Format: NLM
Share it on

J Transl Int Med. 2015 Jun-Sep;3(3):89-92. doi: 10.1515/jtim-2015-0013. Epub 2015 Sep 30.

Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease.

Journal of translational internal medicine

Pan-Wen Tian, Fu-Qiang Wen

Affiliations

  1. Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.

PMID: 27847895 PMCID: PMC4936458 DOI: 10.1515/jtim-2015-0013

Abstract

Airway mucus hypersecretion is one of the most important features of chronic obstructive pulmonary disease (COPD). Airway mucus hypersecretion in COPD patients results in outcomes such as rapid decline of lung function, poor quality of life, and high rate of acute exacerbation, hospitalization and mortality. Nonpharmacologic treatments for airway mucus hypersecretion in COPD include smoking cessation and physical rehabilitation. Pharmacologic therapies include expectorants, mucolytics, methylxanthines, beta-adrenergic receptor agonists, anticholinergics, glucocorticoids, phosphodiesterase-4 inhibitors, antioxidants, and antibiotics. Novel drugs with promising prospects are currently under clinical trials.

Keywords: chronic obstructive; mucus hypersecretion; pulmonary disease

References

  1. Eur Respir J. 1995 Aug;8(8):1333-8 - PubMed
  2. Eur Respir J. 2012 Jul;40(1):28-36 - PubMed
  3. Am Rev Respir Dis. 1992 Oct;146(4):855-9 - PubMed
  4. Am Rev Respir Dis. 1989 Sep;140(3 Pt 2):S49-55 - PubMed
  5. Cochrane Database Syst Rev. 2011 May 11;(5):CD002309 - PubMed
  6. Lancet. 2009 Aug 29;374(9691):695-703 - PubMed
  7. Lancet. 2003 Feb 8;361(9356):449-56 - PubMed
  8. Respir Care. 2007 Sep;52(9):1198-206; discussion 1206-9 - PubMed
  9. Lancet Respir Med. 2014 Mar;2(3):187-94 - PubMed
  10. Chest. 2000 May;117(5 Suppl 1):303S-17S - PubMed
  11. N Engl J Med. 2011 Aug 25;365(8):689-98 - PubMed
  12. Rev Mal Respir. 1992;9(5):503-7 - PubMed
  13. Lancet. 2005 Apr 30-May 6;365(9470):1552-60 - PubMed
  14. Chest. 2009 Apr;135(4):975-82 - PubMed
  15. Respir Care. 2009 Mar;54(3):327-33 - PubMed
  16. Chest. 2004 May;125(5):1726-34 - PubMed
  17. Am J Respir Crit Care Med. 1996 May;153(5):1530-5 - PubMed
  18. Respir Res. 2010 Sep 10;11:122 - PubMed
  19. N Engl J Med. 2010 Dec 2;363(23 ):2233-47 - PubMed
  20. Chest. 2006 Oct;130(4):1129-37 - PubMed
  21. Int Immunopharmacol. 2013 Nov;17(3):625-32 - PubMed
  22. Chest. 2011 Sep;140(3):626-33 - PubMed
  23. Am J Respir Crit Care Med. 2008 Dec 1;178(11):1139-47 - PubMed

Publication Types